Well, the first dosing group took place somewhere is early 2016. Thats over 2 years ago.
We completed the first dosing group of 3 subjects in the Phase I clinical trial, with no evidence of serious adverse events or dose-limiting toxicities.
In a trial for late stage ovarian cancer, the above is not much information to consider it acceptable reported results. Of only 3 subjects, I wonder how many were able to complete the full treatment protocol.. Remember, late stage OC subjects previously treated qualifying for Oncolix's trial, typically have many other complications and unfortunately a rather short life expectancy.
In the extreme, 3 subjects may have only lasted 1 week before having to drop out or worse. So, no AEs isnt saying much without qualification.
Market Data 
Markets 
AI
